Hsp90 Inhibition Counters JAK/STAT-Signaling Diseases

Hsp90 inhibition has been found to be a successful therapeutic approach for combating diseases that use JAK/STAT signaling for tumor growth. In in vivo and in vitro models, researchers showed that the small molecule Hsp90 inhibitor ganetespib exhibited potent activity in tumor cells dependent specifically on JAK2 signaling. Specifically, ganetespib sustained depletion of JAK2 including active JAK2V617Fmutant, subsequently decreasing STAT activity and reducing STAT-target gene expression.

 

Complete results are published online inPLoS One (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018552).

Related Items
Combination Immunotherapy the New Standard for Patients with Metastatic Melanoma
Walter Alexander
TOP - August 2016, Vol 9, No 3 published on August 3, 2016 in Melanoma, Drug Therapies
Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation
Alice Goodman
TOP November 2015 Vol 8 No 4 published on December 3, 2015 in Drug Therapies
New End Points Create Novel Challenges for Health Plans in Oncology Drug Management
James T. Kenney Jr, RPh, MBA
Web Exclusives published on August 25, 2011 in Drug Therapies
Postmenopausal Hormone Therapy Reduces Risk for Some Cancers
TOP - Daily published on June 15, 2011 in Drug Therapies
Drug Exposure, Response Rates Associated with Higher Doses of Melphalan
Cristi Radford, MS, CGC
Web Exclusives published on May 26, 2011 in Drug Therapies
Pharmacist Review of Palonosetron Use Has Potential to Capture Inappropriate Use and Save Money
Wayne Kuznar
Web Exclusives published on February 17, 2011 in Drug Therapies
Preoperative Anti-HER2 Agents Yield Benefits
Caroline Helwick
Web Exclusives published on December 23, 2010 in Drug Therapies, In the News
Last modified: July 22, 2021